Calendar
CIEN Tissue Bank SCAP-AD digital test
  • Spanish
  • English
Logo Logo Logo
Menu
The Center

The Center

The Center
The Center See all See all
    Introduction Board of Trustees Scientific Direction Management External scientific advisory board Research Ethics Committee of the Carlos III Health Institute (Instituto de Salud Carlos III). Team
Platforms

Platforms

Platforms
Platforms See all See all
    Clinical Evaluation Platform Biomarkers/Biochemistry and Molecular Genetics Laboratory Platform Neuroimaging Platform Neuropathology and Biobank Platform Database and Bioinformatics Platform
Research projects

Research projects

Research projects
Research projects See all See all
    SCAP-AD The VARS Project FluiDx-AD Madrid - FTD Consortium Projects with private financing Projects with public financing Major Projects History
Employment and Grants

Employment and Grants

Employment and…
Employment and Grants See all See all
    Employment Grants Employment exchange
Collaborate

Collaborate

Collaborate
Collaborate See all See all
    Friends of the CIEN Foundation Solidarity cards for weddings and events Gift research on Alzheimer’s with the solidarity bracelet designed by Morè Post-mortem brain donation for research Become a volunteer
Service benefits
Outreach

Outreach

Outreach
Outreach See all See all
    Events News Annual Report Our congress Memorables Film Festival Anticipate Alzheimer's Newsletter Calendar CIEN Seminar Series CIEN in the media
Contact
Accessibility

News

News / FluiDx-AD, a European project to revolutionise…

FluiDx-AD, a European project to revolutionise Alzheimer's diagnosis with non-invasive testing

FluiDx-AD, a European project to revolutionise Alzheimer's diagnosis with non-invasive testing
Last news
CIEN participates in a key study on tau-PET recently published in JAMA
02/07/2025
CIEN participates in a key study on tau-PET recently published…
Resounding Success at the 3rd Open Day of the CIEN Tissue Bank
25/06/2025
Resounding Success at the 3rd Open Day of the CIEN…
The Reina Sofía Foundation and CIEN organize the 2nd International Congress on ALS "Manolo Barrós" in Madrid
19/06/2025
The Reina Sofía Foundation and CIEN organize the 2nd International…
06 March 2025
Share: twitter

The CIEN - Centre for Research in Neurological Diseases is part of the FluiDx-AD consortium, an innovative project funded by the Horizon Europe programme of the European Union, which seeks to improve early diagnosis of Alzheimer's disease through minimally invasive and accessible tests and which is directly linked to CIEN's research and investment strategy in recent years.

Coordinated by the Oslo University Hospital, FluiDx-AD involves ten European institutions in a research consortium, including hospitals, research centres and technology companies. It aims to develop a set of diagnostic tools based on saliva and blood samples, offering a simpler and more affordable alternative to current invasive and expensive methods, such as lumbar punctures or advanced neuroimaging.

Towards faster and more accurate diagnosis

Currently, it can take more than a year to diagnose Alzheimer's disease, limiting early access to treatments that could modify the course of the disease. FluiDx-AD will develop three new tests to improve early detection:

  • SalivaDx-AD: a saliva test designed to detect Alzheimer's risk in its early stages, facilitating mass screening.
  • PlasmaDx-AD: a highly accurate blood test to confirm the diagnosis in people with clinical, psychological or behavioural signs of Alzheimer's disease.
  • BloodCellDx-AD: a blood test to assess the risk of adverse effects associated with new anti-amyloid drugs that, after decades without new drug developments, are beginning to be used in the US and Europe.

“Alzheimer's is a public health challenge with a growing incidence. The possibility of having faster and more accessible diagnostic tools will transform the way we approach the disease, allowing earlier and more personalised diagnoses, a goal we have been working on for years, and recently in personalised medicine projects,” says Pascual Sánchez Juan, CIEN's scientific director.

Impact on research and emerging treatments

In addition to improving detection, FluiDx-AD will also contribute to the optimisation of clinical trials for disease-modifying therapies. The new tests will help to better select patients and reduce the risks of adverse effects, such as those related to amyloid accumulation in the brain.

“The approval of new treatments has created an urgent need for biomarkers to identify which patients are best suited to a pharmacological approach that may have adverse side effects. This project is a key step towards making precision medicine a reality in the field of Alzheimer's disease,” says Sánchez Juan.

The FluiDx-AD consortium includes leading institutions in the study of Alzheimer's disease, such as the Oslo University Hospital, the University of Helsinki, the Università Cattolica del Sacro Cuore in Rome and CIEN in Madrid, which will contribute its biobank and clinical samples to the research, and Alzheimer Europe, which will be responsible for communication issues, relations with public administrations and ethical considerations.

With the backing of the European Commission, this project represents a crucial advance in the fight against Alzheimer's, improving not only the diagnosis but also the quality of life of patients and their families.

image
Subscribe to our Newsletter Subscribe me
logo-cien-white
logo-cien-white

The Center for Research on Neurological Diseases (CIEN) has among its main objectives to support, promote, and coordinate research into neurodegenerative diseases, with a primary focus on Alzheimer’s and other related conditions.

Of interest
  • Fundación Reina Sofia
  • Employment / Grants
  • Donations
  • Become a friend
  • Information system
Contact
  • C/ Valderrebollo, 5. Centro Alzheimer Fundación Reina Sofía. 28031 - Madrid
  • info@fundacioncien.es
  • 913 852 200
twitter
Copyright © 2024. CIEN - All rights reserved. Privacy policy Legal Notice Cookies Policy Accessibility
Designed by Fontventa S.L.